GLP-1 Medications
for Weight Loss
A comprehensive guide to GLP-1 receptor agonists and dual-agonist medications used for weight management. Compare dosing schedules, clinical trial results, side effects, and costs to understand your options.
Medications
15 drugsSemaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the naturally occurring incretin hormone GLP-1. It binds to GLP-1 receptors in the pancreas to stimulate insulin secretion, suppresses glucagon release, and slows gastric emptying to promote satiety. In the brain, semaglutide acts on hypothalamic appetite centers to reduce hunger and food cravings, leading to decreased caloric intake and sustained weight loss.
Tirzepatide
Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates both GIP and GLP-1 receptors, producing enhanced insulin secretion, reduced glucagon release, and slowed gastric emptying. The addition of GIP receptor agonism is believed to amplify weight loss beyond what GLP-1 alone achieves, potentially through complementary effects on fat metabolism, appetite regulation, and energy expenditure.
Ozempic
Ozempic contains semaglutide, a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. It enhances glucose-dependent insulin secretion, suppresses glucagon, and delays gastric emptying. By acting on brain appetite centers, it also reduces hunger and caloric intake, which contributes to weight loss as a secondary benefit in patients with type 2 diabetes.
Wegovy
Wegovy contains semaglutide at a higher dose than Ozempic (up to 2.4 mg vs 2 mg weekly). It activates GLP-1 receptors to reduce appetite, slow gastric emptying, and increase satiety. Acting on hypothalamic appetite centers, it reduces food cravings and overall caloric intake. The higher dose formulation was specifically optimized for maximum weight-loss efficacy in individuals with obesity or overweight.
Mounjaro
Mounjaro contains tirzepatide, the first dual GIP and GLP-1 receptor agonist. By activating both incretin receptors, it produces robust insulin secretion, glucagon suppression, and appetite reduction. The dual mechanism is believed to offer enhanced metabolic benefits compared to GLP-1-only agonists, including greater glucose lowering and substantially more weight loss.
Zepbound
Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist that activates both incretin pathways to produce substantial appetite suppression, delayed gastric emptying, and improved metabolic signaling. The dual mechanism targets complementary pathways in the gut, pancreas, and brain to reduce caloric intake and promote sustained weight loss that exceeds what GLP-1-only medications achieve.
Liraglutide
Liraglutide is a first-generation GLP-1 receptor agonist with 97% homology to native human GLP-1. It binds to and activates GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. Liraglutide has a half-life of approximately 13 hours, requiring once-daily injection. While effective for both glycemic control and weight management, it produces less weight loss than the newer once-weekly semaglutide.
Rybelsus
Rybelsus contains oral semaglutide co-formulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that protects semaglutide from degradation in the stomach and facilitates its absorption across the gastric mucosa. Once absorbed, it works identically to injectable semaglutide: activating GLP-1 receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central nervous system effects.
Retatrutide
Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. The GLP-1 and GIP components reduce appetite and improve glucose metabolism, similar to tirzepatide. The novel addition of glucagon receptor agonism is hypothesized to increase energy expenditure, enhance hepatic fat oxidation, and promote thermogenesis. This triple mechanism may explain the unprecedented weight loss seen in early trials, potentially exceeding what dual agonists achieve.
Compounded Semaglutide
Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy — the GLP-1 receptor agonist semaglutide. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance insulin secretion. However, compounded versions are not manufactured under the same rigorous FDA-approved process as Novo Nordisk products. They are prepared by compounding pharmacies using bulk semaglutide sodium salt, which differs chemically from the semaglutide base used in FDA-approved products.
GLP-1 Cost Guide
GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, reducing appetite, slowing gastric emptying, and improving insulin sensitivity. This guide covers the cost landscape for all FDA-approved GLP-1 medications used for weight management and type 2 diabetes, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza).
GLP-1 Insurance Coverage
This guide covers insurance coverage for all GLP-1 receptor agonist medications, including how to navigate prior authorization, step therapy requirements, coverage denials, and the appeals process.
GLP-1 Long-Term Safety
This page analyzes the long-term safety data for GLP-1 receptor agonists, drawing on clinical trial evidence spanning up to 4 years of follow-up. Topics include thyroid C-cell tumor risk, pancreatitis, gallbladder disease, muscle loss, and overall safety signals from the SELECT and SUSTAIN cardiovascular outcomes trials.
GLP-1 and Alcohol
This page covers the interactions between alcohol and GLP-1 receptor agonist medications, including reduced alcohol tolerance, blood sugar effects, liver considerations, and practical guidance for patients.
GLP-1 and Exercise
This page covers exercise recommendations for patients taking GLP-1 receptor agonist medications, with emphasis on the critical importance of resistance training for muscle preservation during pharmacological weight loss.
Compare Medications
Tirzepatide vs Semaglutide: Which GLP-1 Medication Is Better?
Ozempic vs Wegovy: Understanding the Differences Between Two Semaglutide Products
Ozempic vs Mounjaro: Comparing the Two Most Prescribed GLP-1 Medications
Wegovy vs Zepbound: Which Weight Loss Injection Produces Better Results?
Saxenda vs Ozempic: How First-Generation and Second-Generation GLP-1s Compare
Oral vs Injectable Semaglutide: How Rybelsus Compares to Ozempic and Wegovy
Related Tools & Guides
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary.